David Sinclair/X
May 4, 2026, 17:00
David Sinclair: NMN Modulates Immune Response in Antibody-Mediated Bleeding Disorder
David Sinclair, Author and Host of Lifespan, shared a post on X about a recent article by Huiyuan Li et al., published in Nature, adding:
”New Clinical Trial Result:
NMN suppresses harmful antibody-driven immune attacks to alleviate a common bleeding disorder. Authors suggest it may help other autoimmune diseases like lupus and rheumatoid arthritis.”
Title: Low-dose oral nicotinamide mononucleotide for immune thrombocytopenia: a phase 1/2 trial
Authors: Huiyuan Li, Yuan Xu, Yunfei Chen, Lulu Ji, Yanmei Xu, Wenting Zheng, Ting Sun, Rongfeng Fu, Xiaolei Pei, Xiaofan Liu, Feng Xue, Wei Liu, Wentian Wang, Ying Chi, Renchi Yang, Jun Wei, Lei Zhang
Stay updated on all scientific advances with Hemostasis Today.
-
May 15, 2026, 04:34Aryabhatta Sadhu: Honoured to Speak at The 5th European Congress on Hematology and Blood Disorders
-
May 15, 2026, 04:28Ashkan Shoamanesh: Thrilled to Be Leading The Global INTERCEPT Trial
-
May 15, 2026, 04:00Danny Hsu: Join The THANZ Webinar on The Art and Science of Anticoagulation Stewardship
-
May 15, 2026, 03:48Deepak Yadav: What If the Way We Classify Stroke Tissue Is Too Simplistic for Modern Stroke Care?
-
May 15, 2026, 03:32Damon Race: Can Gene Therapy Deliver Durable Expression Over Time?
-
May 14, 2026, 17:17Abhijit D: Reticulocyte Count Methods in Hematology Laboratories
-
May 14, 2026, 16:46Michele Romoli: Neurointerventional Workforce Gaps and Stroke Thrombectomy Access in Europe
-
May 14, 2026, 16:37Reyes Calzada Bau: What It Means to Live with Immune Thrombocytopenia
-
May 14, 2026, 16:34Julia Owens: Improving Acute Stroke Care for Patients Without Timely Intervention